Tareen / Greydanus / Jafferany | Pediatric Psychodermatology | E-Book | sack.de
E-Book

E-Book, Englisch, 596 Seiten

Reihe: Health, Medicine and Human Development

Tareen / Greydanus / Jafferany Pediatric Psychodermatology


A Clinical Manual of Child and Adolescent Psychocutaneous Disorders

E-Book, Englisch, 596 Seiten

Reihe: Health, Medicine and Human Development

ISBN: 978-3-11-027393-9
Verlag: De Gruyter
Format: PDF
 Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

Psychodermatology is a relatively new field in evolution and thus, there is a comparative paucity of information in general. However, when it comes to children and adolescents there is a complete vacuum of information as no other book has aimed to specifically address the psychodermatological issues facing this particular population. For assessment, diagnosis, comprehensive treatment of children with psychodermatologic conditions and establishing a relationship between skin and psyche, there is a lack of clear and relevant clinical information about these complex disorders. The complexity of these disorders is related to lack of understanding in genetic, embryonic, physiologic, neuroimmunologic, neurocutaneous, stress-related neuromodulation, and psychosomatic interconnections. This book presents a clinically relevant approach to the management of psychodermatologic issues encountered in normal practice. Various classifications and major categories that are discussed include psychophysiologic disorders, psychiatric conditions with dermatologic manifestations, dermatologic disorders predisposing to psychiatric disorders, systemic diseases with psychodermatological manifestations, and special issues in management of psychocutaneous disorders in children and adolescents.
Tareen / Greydanus / Jafferany Pediatric Psychodermatology jetzt bestellen!

Zielgruppe

Pediatricians, Physicians, Family Physicians, Internists, Dermatologists, Psychiatrists, Psychologists, Psychodermatologists, and Paramedical Staff; Academic Libraries

Autoren/Hrsg.

Tareen, Ruqiya Shama
Greydanus, Donald E.
Jafferany, Mohammad
Patel, Dilip R.
Merrick, Joav

Fachgebiete

Weitere Infos & Material

1;Foreword I;23
2;Foreword II;27
3;Preface;29
4;Author index;37
5;Abbreviations;41
6;Part I: INTERFACE OF DERMATOLOGY AND PSYCHIATRY;47
6.1;1 Perspectives on management of pediatric dermatologie disorders;49
6.1.1;1.1 Introduction;49
6.1.2;1.2 Skin infections and infestations;49
6.1.2.1;1.2.1 Bacterial infections;49
6.1.2.2;1.2.2 Viral infections;61
6.1.3;1.3 HIV/AIDS;65
6.1.3.1;1.3.1 Non-infectious skin lesions;65
6.1.3.2;1.3.2 Bacterial infections in HIV;65
6.1.3.3;1.3.3 Viral infections in HIV;66
6.1.3.4;1.3.4 Fungal infections in HIV;66
6.1.3.5;1.3.5 Fungal infections;67
6.1.3.6;1.3.6 Topical antifungals;71
6.1.3.7;1.3.7 Infestations;72
6.1.4;1.4 Dermatitis;75
6.1.4.1;1.4.1 Irritant dermatitis;75
6.1.4.2;1.4.2 Dry-skin dermatitis;75
6.1.4.3;1.4.3 Seborrheic dermatitis;75
6.1.4.4;1.4.4 Allergic dermatitides;76
6.1.4.5;1.4.5 Idiopathic dermatitides;79
6.1.5;1.5 Hypersensitivity;79
6.1.5.1;1.5.1 Urticaria;79
6.1.5.2;1.5.2 Drug eruptions;81
6.1.6;1.6 Miscellaneous skin conditions;83
6.1.6.1;1.6.1 Acne vulgaris;83
6.1.6.2;1.6.2 Nevi;87
6.1.6.3;1.6.3 Papulosquamous disorders;90
6.1.6.4;1.6.4 Lichens;92
6.1.6.5;1.6.5 Psoriasis;95
6.1.7;1.7 Dermatologic manifestations of systematic disorders;98
6.1.7.1;1.7.1 Pruritus without rash;98
6.1.7.2;1.7.2 Inflammatory bowel disease (IBD);99
6.1.7.3;1.7.3 Erythema nodosum;99
6.1.7.4;1.7.4 Pyoderma gangrenosum;99
6.1.7.5;1.7.5 Less common skin manifestations;99
6.1.7.6;1.7.6 Management;99
6.1.8;1.8 Collagen vascular disease;100
6.1.8.1;1.8.1 Lupus erythematosus (SLE);100
6.1.8.2;1.8.2 Dermatomyositis;100
6.1.8.3;1.8.3 Juvenile idiopathic arthritis;100
6.1.8.4;1.8.4 Management;100
6.1.9;1.9 Endocrinologic disorders;101
6.1.9.1;1.9.1 Thyroid disorders;101
6.1.9.2;1.9.2 Diabetes mellitus;101
6.1.9.3;1.9.3 Adrenal disorders;101
6.1.9.4;1.9.4 Management;102
6.1.10;1.10 Hair and nails;102
6.1.10.1;1.10.1 Alopecia areata;102
6.1.10.2;1.10.2 Telogen effluvium;104
6.1.10.3;1.10.3 Androgenic alopecia;104
6.1.10.4;1.10.4 Trichotillomania;105
6.1.10.5;1.10.5 Traction alopecia;105
6.1.10.6;1.10.6 Hirsutism and hypertrichosis;105
6.1.10.7;1.10.7 Hair changes with systemic disease;106
6.1.10.8;1.10.8 Infection;106
6.1.10.9;1.10.9 Bacterial;108
6.1.10.10;1.10.10 Fungal;109
6.1.10.11;1.10.11 Onychodystrophy;110
6.1.10.12;1.10.12 Nail changes with systemic and nutritional disorders;111
6.2;2 Psychoneuroimmunology and other interactions between skin and psyche;115
6.2.1;2.1 Introduction;115
6.2.1.1;2.1.1 History of psychodermatology;116
6.2.1.2;2.1.2 Classification of psychodermatologic disorders;118
6.2.1.3;2.1.3 Psychological perspective of skin;118
6.2.1.4;2.1.4 Skin, mind, and the embryological embrace;120
6.2.2;2.2 Psychoneuroimmunology;121
6.2.2.1;2.2.1 Neuroendocrine response to stress;121
6.2.2.2;2.2.2 Immune response and central nervous system;122
6.2.2.3;2.2.3 Immune response and peripheral nervous system;123
6.2.2.4;2.2.4 Immune response and skin disease;123
6.2.2.5;2.2.5 Immune response and psychiatric disease;125
6.2.3;2.3 Conclusion;126
6.3;3 A clinician’s approach to psychocutaneous diseases in adolescents: Untying the Gordian knot;129
6.3.1;3.1 Introduction;129
6.3.1.1;3.1.1 History taking skills in adolescent patients;129
6.3.2;3.2 Interviewing the adolescent patient;131
6.3.2.1;3.2.1 Confidentiality;133
6.3.2.2;3.2.2 Parental confidentiality;133
6.3.2.3;3.2.3 Health questionnaires;133
6.3.2.4;3.2.4 Interview techniques;134
6.3.2.5;3.2.5 Active listening skills;135
6.3.3;3.3 Concepts of the physical examination;136
6.3.4;3.4 Successful management of the adolescent patient;136
6.3.4.1;3.4.1 Informed consent;136
6.3.4.2;3.4.2 Shared decision makings;137
6.3.4.3;3.4.3 Improving compliance;138
6.3.5;3.5 Conclusion;138
6.4;4 Quality of life issues in children and adolescents with dermatological conditions and their wider impact on the family and society;141
6.4.1;4.1 Introduction;141
6.4.2;4.2 Pediatric quality of life and its assessment;142
6.4.3;4.3 Skin disease and quality of life;143
6.4.3.1;4.3.1 Impact of skin diseases on children’s quality of life;143
6.4.3.2;4.3.2 Quality of life assessment in children with dermatological conditions;145
6.4.3.3;4.3.3 Children’s Dermatology Life Quality Index (CDLQI);146
6.4.3.4;4.3.4 Infant’s Dermatitis Quality of Life Index (IDQoL);146
6.4.3.5;4.3.5 Impact of skin disease on the quality of life of adolescents;147
6.4.4;4.4 Assessment of adolescents’ quality of life in dermatology;148
6.4.4.1;4.4.1 Teenager’s QoL questionnaire (T-QoL);148
6.4.4.2;4.4.2 Skindex-Teen;149
6.4.4.3;4.4.3 Impact of skin disease on family quality of life: The “greater patient” concept;150
6.4.5;4.5 Assessment of family quality in dermatology;152
6.4.5.1;4.5.1 Family Dermatology Life Quality Index (FDLQI);152
6.4.5.2;4.5.2 Dermatitis Family Impact questionnaire (DFI);153
6.4.5.3;4.5.3 Parents’ Index of Quality of Life in Atopic Dermatitis (PIQoL-AD);154
6.4.5.4;4.5.4 Childhood Atopic Dermatitis Impact Scale (CADIS);154
6.4.5.5;4.5.5 Psoriasis Family Index (PFI);155
6.4.6;4.6 Societal impact of childhood dermatological conditions;155
6.4.7;4.7 Conclusions;156
7;Part II: PSYCHOPHYSIOLOGIC DISORDERS;163
7.1;5 Atopic dermatitis: a psychocutaneous review;165
7.1.1;5.1 Introduction;165
7.1.1.1;5.1.1 Epidemiology;165
7.1.2;5.2 Pathophysiologic factors in atopic dermatitis;166
7.1.2.1;5.2.1 Genetic predisposition;166
7.1.2.2;5.2.2 Socio-economic status;166
7.1.2.3;5.2.3 Family size;166
7.1.2.4;5.2.4 Food allergens;166
7.1.3;5.3 Psychoneuroimmunologic factors;167
7.1.3.1;5.3.1 Breast feeding;167
7.1.3.2;5.3.2 Environmental allergens;167
7.1.4;5.4 Psychophysiological aspects of atopic dermatitis;168
7.1.4.1;5.4.1 Impact of stress on the immunological system;168
7.1.4.2;5.4.2 Psychoanalytic hypothesis;169
7.1.4.3;5.4.3 Biopsychosocial model;170
7.1.4.4;5.4.4 Psychological dysregulation due to atopic dermatitis;170
7.1.5;5.5 Clinical features;171
7.1.6;5.6 Diagnosis;171
7.1.6.1;5.6.1 Allergy Testing;173
7.1.6.2;5.6.2 Differential Diagnosis;174
7.1.7;5.7 Management;174
7.1.7.1;5.7.1 Prevention of relapse;174
7.1.7.2;5.7.2 Food allergens;175
7.1.7.3;5.7.3 Aeroallergens;175
7.1.7.4;5.7.4 Optimizing the epidermal barrier (EB);175
7.1.7.5;5.7.5 Hydration therapy;176
7.1.7.6;5.7.6 Management of pruritus;176
7.1.7.7;5.7.7 Topical corticosteroids;177
7.1.7.8;5.7.8 Topical immunomodulators;180
7.1.8;5.8 Systematic treatment of atopic dermatits;180
7.1.8.1;5.8.1 Antihistamines;180
7.1.8.2;5.8.2 Phototherapy;181
7.1.8.3;5.8.3 Antibiotics;181
7.1.8.4;5.8.4 Systemic corticosteroids;182
7.1.8.5;5.8.5 Immunomodulators;182
7.1.8.6;5.8.6 Cyclosporine;183
7.1.8.7;5.8.7 Azathioprine;183
7.1.8.8;5.8.8 Infliximab;183
7.1.8.9;5.8.9 Interferon-.;184
7.1.8.10;5.8.10 Leukotriene inhibitors;184
7.1.9;5.9 Psychiatric comorbidities;184
7.1.9.1;5.9.1 Family dynamics;185
7.1.9.2;5.9.2 Internalizing and externalizing behaviors;185
7.1.9.3;5.9.3 Anxiety and depression;186
7.1.9.4;5.9.4 Personality traits;186
7.1.10;5.10 Management of psychiatric comorbidities;187
7.1.10.1;5.10.1 Multidisciplinary approach;187
7.1.10.2;5.10.2 Psychoeducation;187
7.1.10.3;5.10.3 Psychosocial assessment;187
7.1.10.4;5.10.4 Psychiatric symptoms review;188
7.1.10.5;5.10.5 Quality of life assessment;188
7.1.10.6;5.10.6 Psychodynamic therapy;188
7.1.10.7;5.10.7 Cognitive behavioral therapy;189
7.1.10.8;5.10.8 Behavioral modifications;189
7.1.10.9;5.10.9 Psychotropic medications;189
7.1.11;5.11 Conclusion;190
7.2;6 Psoriasis and children: A psychological approach;193
7.2.1;6.1 Introduction;193
7.2.1.1;6.1.1 Epidemiology;194
7.2.2;6.2 Dermatological clinical features;194
7.2.2.1;6.2.1 Plaque psoriasis;195
7.2.2.2;6.2.2 Guttate psoriasis;195
7.2.2.3;6.2.3 Erythrodermic psoriasis;195
7.2.2.4;6.2.4 Pustular psoriasis;196
7.2.2.5;6.2.5 Psoriatic arthritis;197
7.2.2.6;6.2.6 Inverse psoriasis;197
7.2.3;6.3 Psychological clinical features;198
7.2.3.1;6.3.1 Differential diagnosis;200
7.2.3.2;6.3.2 Psychotherapeutic intervention;201
7.2.3.3;6.3.3 Psychotherapy;202
7.2.4;6.4 Conclusions;205
7.3;7 The acnes: Acne vulgaris, acne rosacea, and acne excoriée;209
7.3.1;7.1 Acne Vulgaris;209
7.3.1.1;7.1.1 Introduction;209
7.3.1.2;7.1.2 Epidemiology;209
7.3.1.3;7.1.3 Pathogenesis;213
7.3.1.4;7.1.4 Classification;214
7.3.1.5;7.1.5 Management;214
7.3.1.6;7.1.6 Teratogenicity and isotretinoin;225
7.3.1.7;7.1.7 Depression, suicidality, and isotretinoin;226
7.3.2;7.2 Acne Rosacea;230
7.3.2.1;7.2.1 Pathophysiology;231
7.3.2.2;7.2.2 Management of acne rosacea;232
7.3.3;7.3 Acne Variants;233
7.3.4;7.4 Conclusion;233
7.4;8 Psychogenic purpura (Gardner-Diamond syndrome);239
7.4.1;8.1 Introduction;239
7.4.2;8.2 History;239
7.4.3;8.3 Etiology and pathogenesis;240
7.4.4;8.4 Clinical features;241
7.4.5;8.5 Differential diagnosis;241
7.4.5.1;8.5.1 Disease course;241
7.4.5.2;8.5.2 Histopathology;241
7.4.5.3;8.5.3 Laboratory testings;242
7.4.5.4;8.5.4 Psychological disturbances;242
7.4.6;8.6 Treatment approaches and recommendations;242
7.4.7;8.7 Conclusion;243
8;Part III: PSYCHIATRIC DISORDERS WITH DERMATOLOGIC MANIFESTATIONS;245
8.1;9 Body dysmorphic disorder in adolescents;247
8.1.1;9.1 Introduction;247
8.1.2;9.2 Definition;248
8.1.2.1;9.2.1 Epidemiology;249
8.1.2.2;9.2.2 Clinical features;249
8.1.2.3;9.2.3 Differential diagnosis;250
8.1.3;9.3 Management;251
8.1.3.1;9.3.1 Preliminary considerations;251
8.1.3.2;9.3.2 The clinical interview;252
8.1.3.3;9.3.3 Assessment;252
8.1.3.4;9.3.4 Patient education;254
8.1.3.5;9.3.5 Treatment;254
8.1.4;9.4 Other treatment techniques;256
8.1.4.1;9.4.1 Anxiety management training (AMT);256
8.1.4.2;9.4.2 Eye movement desensitization and reprocessing (EMDR);257
8.1.4.3;9.4.3 Family therapy;257
8.1.4.4;9.4.4 Group therapy;257
8.1.4.5;9.4.5 Metaphors;257
8.1.4.6;9.4.6 Mindfulness;258
8.1.4.7;9.4.7 Intervention;258
8.1.4.8;9.4.8 Nonpsychiatric medical treatment;258
8.1.4.9;9.4.9 Final management considerations;259
8.1.5;9.5 Conclusions;259
8.2;10 Delusional infestation in childhood, adolescence, and adulthood;263
8.2.1;10.1 Introduction;263
8.2.2;10.2 How to diagnose a delusion;264
8.2.3;10.3 Primary and secondary delusional infestation;265
8.2.4;10.4 The context of children and adolescence;266
8.2.5;10.5 Clinical pictures;267
8.2.5.1;10.5.1 Case one;267
8.2.5.2;10.5.2 Case two;268
8.2.5.3;10.5.3 Case Three;269
8.2.5.4;10.5.4 Commentary on these three cases;270
8.2.6;10.6 Delusional elaboration (“Wahnarbeit”);270
8.2.7;10.7 Prevalence of delusional infestation;272
8.2.7.1;10.7.1 Treatment;273
8.2.7.2;10.7.2 Which antipsychotic in DI?;274
8.2.8;10.8 Antipsychotics;276
8.2.9;10.9 Conclusion;278
8.3;11 Dermatitis artefacta, skin picking, and other self-injurious behaviors: A psychological perspective;283
8.3.1;11.1 Introduction;283
8.3.2;11.2 Epidemiology;285
8.3.3;11.3 Etiology;287
8.3.4;11.4 Clinical features;289
8.3.4.1;11.4.1 Dermatitis Artefacta;291
8.3.4.2;11.4.2 Skin picking;292
8.3.4.3;11.4.3 Self-mutilation behavior;292
8.3.5;11.5 Differential diagnosis;294
8.3.6;11.6 Management;294
8.3.6.1;11.6.1 Pharmacological Treatment;297
8.3.6.2;11.6.2 Psychotherapy;297
8.3.6.3;11.6.3 Issues with Treatment;301
8.3.7;11.7 Conclusions;303
8.4;12 Trichotillomania;307
8.4.1;12.1 Introduction;307
8.4.2;12.2 Definition;307
8.4.3;12.3 Differential diagnosis;308
8.4.4;12.4 Assessment;310
8.4.5;12.5 Management;312
8.4.5.1;12.5.1 Psychotherapy;313
8.4.5.2;12.5.2 Medication;313
8.4.6;12.6 Conclusions: Future directions;314
8.5;13 Psychogenic pruritus with particular emphasis on children and adolescents;317
8.5.1;13.1 Introduction;317
8.5.2;13.2 Epidemiology;318
8.5.3;13.3 Clinical features;319
8.5.4;13.4 Differential diagnosis;320
8.5.5;13.5 Management;321
8.5.6;13.6 Conclusion;323
9;Part IV: DERMATOLOGIC DISORDERS PREDISPOSING TO PSYCHIATRIC DISORDERS;327
9.1;14 Disorders of hair loss;329
9.1.1;14.1 Introduction;329
9.1.2;14.2 Causes of hair loss;329
9.1.3;14.3 Diagnostic approach to hair loss;331
9.1.3.1;14.3.1 History;331
9.1.3.2;14.3.2 Examination;331
9.1.3.3;14.3.3 Laboratory investigation;332
9.1.4;14.4 Tinea capitis;332
9.1.5;14.5 Telogen effluvium;333
9.1.6;14.6 Alopecia areata;333
9.1.7;14.7 Male pattern hair loss;334
9.1.8;14.8 Hair Loss due to Chemotherapy;334
9.1.9;14.9 Psychiatric aspects;334
9.1.9.1;14.9.1 Psychological treatment approaches;336
9.1.10;14.10 Conclusion;337
9.2;15 Disorders of skin pigmentation;341
9.2.1;15.1 Introduction;341
9.2.2;15.2 Disorders of hypopigmentation;342
9.2.2.1;15.2.1 Vitiligo;342
9.2.2.2;15.2.2 Albinism;344
9.2.2.3;15.2.3 Postinflammatory hypopigmentation;344
9.2.2.4;15.2.4 Pityriasis alba;345
9.2.2.5;15.2.5 Tinea versicolor;345
9.2.3;15.3 Disorders of hyperpigmentation;346
9.2.3.1;15.3.1 Postinflammatory hyperpigmentation;346
9.2.3.2;15.3.2 Melasma;346
9.2.3.3;15.3.3 Hyperpigmentation associated with medical disorders;346
9.2.3.4;15.3.4 Café-au-lait spots;347
9.2.3.5;15.3.5 Lentigines;347
9.2.4;15.4 Psychological aspects of disorders of pigmentations;347
9.2.4.1;15.4.1 Psychosocial management of disorders of pigmentation;349
9.2.5;15.5 Conclusion;350
9.3;16 Skin adnexal disorders;353
9.3.1;16.1 Hidradenitis suppurativa (HS);353
9.3.1.1;16.1.1 Introduction;353
9.3.1.2;16.1.2 Diagnosis;353
9.3.1.3;16.1.3 Etiology;354
9.3.1.4;16.1.4 Clinical features;355
9.3.1.5;16.1.5 Differential Diagnosis;356
9.3.2;16.2 Hyperhidrosis;357
9.3.2.1;16.2.1 Definition;357
9.3.2.2;16.2.2 Epidemiology;358
9.3.2.3;16.2.3 Etiology;358
9.3.2.4;16.2.4 Clinical features;359
9.3.2.5;16.2.5 Differential diagnosis;359
9.3.2.6;16.2.6 Management;360
9.3.3;16.3 Anhidrotic ectodermal dysplasia;362
9.3.3.1;16.3.1 Definition;362
9.3.3.2;16.3.2 Epidemiology;362
9.3.3.3;16.3.3 Clinical features;362
9.3.3.4;16.3.4 Differential diagnosis;362
9.3.3.5;16.3.5 Management;363
9.3.4;16.4 Nevus sebaceous;363
9.3.4.1;16.4.1 Definition;363
9.3.4.2;16.4.2 Epidemiology;363
9.3.4.3;16.4.3 Clinical features;363
9.3.4.4;16.4.4 Differential diagnosis;364
9.3.4.5;16.4.5 Management;364
9.3.5;16.5 Conclusion;364
10;Part V: SYSTEMATIC DISEASES WITH PSYCHODERMATOLOGIC MANIFESTATIONS;367
10.1;17 Neurocutaneous disorders;369
10.1.1;17.1 Introduction;369
10.1.2;17.2 Neurofibromatosis;369
10.1.2.1;17.2.1 Clinical features;371
10.1.2.2;17.2.2 Neuropsychiatric aspects of neurofibromatosis type 1;371
10.1.2.3;17.2.3 Management;372
10.1.2.4;17.2.4 NF1 summary;374
10.1.3;17.3 Tuberous Sclerosis Complex (TSC);374
10.1.3.1;17.3.1 Introduction;374
10.1.3.2;17.3.2 Clinical features of TSC;375
10.1.3.3;17.3.3 Neurologic lesions;375
10.1.3.4;17.3.4 Psychiatric symptoms;375
10.1.3.5;17.3.5 Management;376
10.1.3.6;17.3.6 Treatment of neuropsychiatric problems;376
10.1.4;17.4 Conclusion;378
10.2;18 Collagen vascular disorders: Psychiatric and dermatologic manifestations;381
10.2.1;18.1 Lupus erythematosus (LE);381
10.2.1.1;18.1.1 Epidemiology;381
10.2.1.2;18.1.2 Clinical features;381
10.2.1.3;18.1.3 Cutaneous manifestations;382
10.2.1.4;18.1.4 Neuropsychiatric systemic lupus erythematosus (NPSLE);383
10.2.1.5;18.1.5 Differential diagnosis;386
10.2.1.6;18.1.6 Clinical diagnosis;386
10.2.1.7;18.1.7 Diagnostic workup;388
10.2.1.8;18.1.8 Management;388
10.2.1.9;18.1.9 Treatment of cutaneous lupus lesions;389
10.2.1.10;18.1.10 Treatment of NPSLE;389
10.2.2;18.2 Dermatomyositis;390
10.2.2.1;18.2.1 Epidemiology;390
10.2.2.2;18.2.2 Clinical features;391
10.2.2.3;18.2.3 Cutaneous manifestations;391
10.2.2.4;18.2.4 Psychiatric manifestations;392
10.2.2.5;18.2.5 Management;393
10.2.3;18.3 Rheumatoid Arthritis;394
10.2.3.1;18.3.1 Epidemiology;394
10.2.3.2;18.3.2 Etiopathogenesis;395
10.2.3.3;18.3.3 Clinical features;395
10.2.3.4;18.3.4 Cutaneous manifestations;395
10.2.3.5;18.3.5 Psychiatric manifestations;397
10.2.3.6;18.3.6 Laboratory findings;399
10.2.3.7;18.3.7 Management;400
10.2.3.8;18.3.8 Management of psychiatric issues;402
10.3;19 Psychocutaneous manifestations of endocrine disorders;407
10.3.1;19.1 Introduction;407
10.3.2;19.2 Diabetes Mellitus;407
10.3.2.1;19.2.1 Clinical features;408
10.3.2.2;19.2.2 Dermatological manifestations;409
10.3.2.3;19.2.3 Psychiatric manifestations;411
10.3.2.4;19.2.4 Management of psychiatric conditions;412
10.3.3;19.3 Disorders of growth hormone;413
10.3.3.1;19.3.1 Acromegaly;413
10.3.3.2;19.3.2 Dermatological manifestations;413
10.3.3.3;19.3.3 Psychiatric manifestations;414
10.3.3.4;19.3.4 Diagnostic workup;415
10.3.3.5;19.3.5 Clinical management;415
10.3.3.6;19.3.6 Management of dermatological manifestations;416
10.3.3.7;19.3.7 Management of psychiatric manifestations;416
10.3.4;19.4 Thyroid hormone disorders;416
10.3.4.1;19.4.1 Hypothyroidism;416
10.3.4.2;19.4.2 Hyperthyroidism;417
10.3.4.3;19.4.3 Clinical features of thyroid disorders;417
10.3.4.4;19.4.4 Dermatological manifestations of hypothyroidism;418
10.3.4.5;19.4.5 Dermatological manifestations of hyperthyroidism;419
10.3.4.6;19.4.6 Psychiatric manifestations;419
10.3.4.7;19.4.7 Diagnostic workup;421
10.3.4.8;19.4.8 Management of hypothyroidism;421
10.3.4.9;19.4.9 Management of hyperthyroidism;421
10.3.4.10;19.4.10 Management of psychiatric disorders;423
10.3.5;19.5 Adrenal gland disorders;424
10.3.5.1;19.5.1 Hypoadrenocorticism (adrenal insufficiency [AI] or Addison disease [AD]);424
10.3.5.2;19.5.2 Hyperadrenocorticism (Cushing syndrome);426
10.3.6;19.6 Disorders of parathyroid glands;430
10.3.6.1;19.6.1 Hypoparathyroidism;430
10.3.6.2;19.6.2 Hyperparathyroidism;434
10.3.7;19.7 Disorders of hormones of the reproductive system;436
10.3.8;19.8 Androgen disorders;436
10.3.8.1;19.8.1 Hypogonadism in males;436
10.3.8.2;19.8.2 Androgen disorders in Females;437
10.3.9;19.9 Estrogen disorders;440
10.3.9.1;19.9.1 Estrogen disorders in males;440
10.3.9.2;19.9.2 Estrogen disorders in females;440
10.3.9.3;19.9.3 Psychiatric manifestations of disorders of androgen and estrogens;441
10.3.10;19.10 Conclusion;442
10.4;20 Inborn errors of metabolism with psychiatric and dermatologic features;449
10.4.1;20.1 Introduction;449
10.4.2;20.2 Phenylketonuria [PKU];449
10.4.2.1;20.2.1 Genetics and pathophysiology;450
10.4.2.2;20.2.2 Clinical features;451
10.4.2.3;20.2.3 Cutaneous manifestations;452
10.4.2.4;20.2.4 Psychiatric manifestations;452
10.4.2.5;20.2.5 Laboratory diagnosis;453
10.4.2.6;20.2.6 Management;453
10.4.3;20.3 Hartnup disease;455
10.4.3.1;20.3.1 Genetics and pathophysiology;455
10.4.3.2;20.3.2 Cutaneous manifestations;455
10.4.3.3;20.3.3 Psychiatric manifestations;455
10.4.3.4;20.3.4 Laboratory findings;456
10.4.3.5;20.3.5 Management;456
10.4.4;20.4 Homocystinuria;456
10.4.4.1;20.4.1 Genetics and pathophysiology;456
10.4.4.2;20.4.2 Clinical features;456
10.4.4.3;20.4.3 Cutaneous manifestations;457
10.4.4.4;20.4.4 Psychiatric Manifestations;457
10.4.4.5;20.4.5 Management;458
10.4.5;20.5 Porphyrias;458
10.4.5.1;20.5.1 Genetics and prevalence;458
10.4.5.2;20.5.2 Clinical features;459
10.4.5.3;20.5.3 Cutaneous manifestations;459
10.4.5.4;20.5.4 Psychiatric manifestations;460
10.4.5.5;20.5.5 Laboratory diagnosis;461
10.4.5.6;20.5.6 Management;461
10.4.6;20.6 Conclusion;462
11;Part VI: SPECIAL ISSUES IN MANAGEMENT OF PSYCHOCUTANEOUS DISORDERS;467
11.1;21 Psychiatric complications of dermatological treatments;469
11.1.1;21.1 Introduction;469
11.1.2;21.2 Epidemiology;469
11.1.3;21.3 Clinical features by medication category;470
11.1.3.1;21.3.1 Antibacterial agents;470
11.1.3.2;21.3.2 Antiviral agents;471
11.1.3.3;21.3.3 Corticosteroids;472
11.1.3.4;21.3.4 Dapsone;472
11.1.3.5;21.3.5 Antimalarial agents;472
11.1.3.6;21.3.6 Retinoids;473
11.1.3.7;21.3.7 Interferons;474
11.1.3.8;21.3.8 Other agents;474
11.1.4;21.4 Differential diagnosis;474
11.1.5;21.5 Management;474
11.1.5.1;21.5.1 Drug-drug interactions;475
11.1.5.2;21.5.2 Non-pharmacologic interventions;475
11.1.6;21.6 Conclusion;476
11.2;22 Dermatologic manifestations of psychotropic medications;479
11.2.1;22.1 Introduction;479
11.2.1.1;22.1.1 Epidemiology;479
11.2.2;22.2 Diagnosis;480
11.2.3;22.3 Pathogenesis;481
11.2.4;22.4 Categories;482
11.2.5;22.5 Common adverse cutaneous reactions;482
11.2.5.1;22.5.1 Pruritus;482
11.2.5.2;22.5.2 Exanthematous eruptions;482
11.2.5.3;22.5.3 Urticaria and angioedema;496
11.2.5.4;22.5.4 Fixed drug eruptions;497
11.2.5.5;22.5.5 Photosensitivity;497
11.2.5.6;22.5.6 Pigmentation;498
11.2.5.7;22.5.7 Diaphoresis;498
11.2.5.8;22.5.8 Alopecia;498
11.2.6;22.6 Serious and life-threatening cutaneous reactions;499
11.2.6.1;22.6.1 Erythema multiforme;499
11.2.6.2;22.6.2 Stevens-Johnson Syndrome and Toxic Epidermolysis Necrolysis;499
11.2.6.3;22.6.3 Drug hypersensitivity syndrome;500
11.2.6.4;22.6.4 Vasculitis;501
11.2.6.5;22.6.5 Exfoliative dermatitis;501
11.2.6.6;22.6.6 Anaphylactoid reactions;502
11.2.7;22.7 General dermatologic conditions;502
11.2.7.1;22.7.1 Acneiform eruptions;502
11.2.7.2;22.7.2 Psoriasiform eruption;503
11.2.7.3;22.7.3 Seborrheic eruption;503
11.2.7.4;22.7.4 Lichenoid eruption;503
11.2.8;22.8 Conclusion;504
11.3;23 Non-pharmacological approaches to treat psychocutaneous disorders;507
11.3.1;23.1 Introduction;507
11.3.2;23.2 Non-pharmacological modalities;508
11.3.2.1;23.2.1 Acupuncture;508
11.3.2.2;23.2.2 Aromatherapy;508
11.3.2.3;23.2.3 Biofeedback;509
11.3.2.4;23.2.4 Brief dynamic psychotherapy;510
11.3.2.5;23.2.5 Cognitive behavioral therapy methods;510
11.3.2.6;23.2.6 Emotional freedom techniques (EFT);510
11.3.2.7;23.2.7 Eye Movement Desensitizing and Reprocessing (EMDR);511
11.3.2.8;23.2.8 Hypnosis;511
11.3.2.9;23.2.9 Music;512
11.3.2.10;23.2.10 Placebo;513
11.3.2.11;23.2.11 Suggestion;513
11.3.3;23.3 Conclusion;513
11.4;24 Psychiatric disorders frequently encountered in dermatology practices;517
11.4.1;24.1 Introduction;517
11.4.1.1;24.1.1 Epidemiology;518
11.4.2;24.2 Mood disorders;518
11.4.2.1;24.2.1 Epidemiology;518
11.4.2.2;24.2.2 Diagnosis of depressive disorders;521
11.4.2.3;24.2.3 Differential diagnosis of depressive disorders;522
11.4.2.4;24.2.4 Management of depressive disorders;522
11.4.3;24.3 Bipolar spectrum disorders;523
11.4.3.1;24.3.1 Types of bipolar disorders;524
11.4.3.2;24.3.2 Diagnosis of bipolar disorders;526
11.4.3.3;24.3.3 Differential diagnosis of bipolar disorders;527
11.4.4;24.4 Anxiety spectrum disorders;531
11.4.4.1;24.4.1 Obsessive compulsive disorder;532
11.4.4.2;24.4.2 Social anxiety disorder (SAD);534
11.4.4.3;24.4.3 Eating disorders;537
11.4.5;24.5 Personality disorders (PDs);540
11.4.5.1;24.5.1 Introduction;540
11.4.5.2;24.5.2 Clinical diagnosis;541
11.4.6;24.6 Conclusion;544
12;APPENDIX;547
12.1;25 About the editors;549
12.2;26 FDA approved psychotropic medication indications for children and adolescents;553
12.3;27 Common psychiatric terms;555
12.4;28 Common dermatotologic lesions;559
13;Index;565
14;Plate section;573

Ruqiya Shama Tareen, Donald E. Greydanus, Mohammad Jafferany, and Dilip R. Patel, Michigan State University, East Lansing, Michigan, USA; Joav Merrick, Ministry of Social Affairs and Social Services, Jerusalem, Israel.

Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.